{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:36:35Z","timestamp":1793090195172,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-IAHU-007"],"award-info":[{"award-number":["ANR-23-IAHU-007"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032850","name":"EU4Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032850","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105549","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:29:07Z","timestamp":1787095747000},"page":"105549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The de-centralization perspective for liquid biopsy use in thoracic pathology the way to go"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0431-9353","authenticated-orcid":false,"given":"Paul","family":"Hofman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3211-9957","authenticated-orcid":false,"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105549_bib1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41571-020-0423-x","article-title":"Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice","volume":"18","author":"Aggarwal","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib2","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-026-04263-w","article-title":"Artificial intelligence-powered liquid biopsy in cancer: a paradigm shift in cancer detection and personalized care","author":"AbdelHamid","year":"2026","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.critrevonc.2026.105549_bib3","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jtho.2025.07.009","article-title":"Molecular tumor boards: a consensus statement from the international association for the study of lung cancer","volume":"20","author":"Aldea","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccell.2024.11.009","article-title":"Advances in liquid biopsy: from exploration to practical application","volume":"43","author":"Alix-Panabi\u00e8res","year":"2025","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105549_bib5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.hoc.2023.02.005","article-title":"Convergence of precision oncology and liquid biopsy in non-small cell lung cancer","volume":"37","author":"Al-Obeidi","year":"2023","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"10.1016\/j.critrevonc.2026.105549_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00428-021-03151-0","article-title":"Basic principles of biobanking: from biological samples to precision medicine for patients","volume":"479","author":"Annaratone","year":"2021","journal-title":"Virchows Arch."},{"key":"10.1016\/j.critrevonc.2026.105549_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41571-022-00700-7","article-title":"Barriers in access to oncology drugs - a global crisis","volume":"20","author":"Barrios","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.annonc.2023.01.008","article-title":"Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105549_bib9","first-page":"00760","article-title":"ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe","volume":"S0923-7534","author":"Bayle","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib10","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.annonc.2022.08.089","article-title":"Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)","volume":"33","author":"Bayle","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib11","doi-asserted-by":"crossref","first-page":"7083","DOI":"10.1016\/j.cell.2025.10.020","article-title":"Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction","volume":"188","author":"Black","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105549_bib12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s13046-025-03480-x","article-title":"Detecting actionable mutations from matched plasma-based versus tissue next-generation sequencing in advanced non-small cell lung cancer: a retrospective single centre analysis on site","volume":"44","author":"Bontoux","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105549_bib13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/14737140.2017.1398089","article-title":"The liquid biopsy: a tool for a combined diagnostic and theranostic approach for care of a patient with late-stage lung carcinoma presenting with bilateral ocular metastases","volume":"17","author":"Bouhlel","year":"2017","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.critrevonc.2026.105549_bib14","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/j.cllc.2025.08.009","article-title":"Rebiopsy feasibility and clinical impact on metastatic non-small-cell lung cancer With EGFR\/ALK\/ROS oncogenic driver progression after optimal targeted therapy: a multicenter real-world analysis","volume":"26","author":"Bronstein","year":"2025","journal-title":"Clin. Lung Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105549_bib15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.lungcan.2014.08.016","article-title":"Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01)","volume":"86","author":"Chouaid","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105549_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/0113892029313697240729091922","article-title":"The regulatory landscape of biobanks in europe: from accreditation to intellectual property","volume":"26","author":"Corradi","year":"2025","journal-title":"Curr. Genom."},{"key":"10.1016\/j.critrevonc.2026.105549_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105636","article-title":"Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop","volume":"114","author":"de Jager","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105549_bib18","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamaoncol.2024.1779","article-title":"Circulating tumor DNA-guided de-escalation targeted therapy for advanced non-small cell lung cancer: a nonrandomized controlled trial","volume":"10","author":"Dong","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00428-020-02928-z","article-title":"Biomarker testing in oncology - Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL","volume":"478","author":"Dufraing","year":"2021","journal-title":"Virchows Arch."},{"key":"10.1016\/j.critrevonc.2026.105549_bib20","article-title":"Implementation of circulating tumour DNA multi-target mutation testing in plasma: a perspective from an external quality assessment providers' survey","author":"Fairley","year":"2023","journal-title":"Virchows Arch."},{"key":"10.1016\/j.critrevonc.2026.105549_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/bio.2024.0128","article-title":"Experts speak forum: decarbonization for green biobanking-the current landscape and challenges for the future","volume":"23","author":"Furuta","year":"2025","journal-title":"Biopreserv. Biobank."},{"key":"10.1016\/j.critrevonc.2026.105549_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100301","article-title":"International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors","volume":"8","author":"Fusco","year":"2025","journal-title":"J. Liq. Biopsy"},{"key":"10.1016\/j.critrevonc.2026.105549_bib23","article-title":"Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation","volume":"8","author":"Gosney","year":"2023","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105549_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-026-01781-y","article-title":"Implementing generative artificial intelligence in precision oncology: safety, governance, and significance","volume":"19","author":"Hamamoto","year":"2026","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cllc.2019.07.010","article-title":"Critical assessment in routine clinical practice of liquid biopsy for egfr status testing in non-small-cell lung cancer: a single-laboratory experience (LPCE, Nice, France)","volume":"21","author":"Heeke","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105549_bib26","doi-asserted-by":"crossref","first-page":"922","DOI":"10.21037\/atm-20-7900","article-title":"Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assay","volume":"9","author":"Heeke","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105549_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12967-020-02259-2","article-title":"Prospective evaluation of NGS-based liquid biopsy in untreated late stage non-squamous lung carcinoma in a single institution","volume":"18","author":"Heeke","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105549_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100399","article-title":"Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer","volume":"7","author":"Heitzer","year":"2022","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105549_bib29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Electronic address: clinicalguidelines@esmo.org. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/cells10010168","article-title":"Detecting resistance to therapeutic ALK inhibitors in tumor tissue and liquid biopsy markers: an update to a clinical routine practice","volume":"10","author":"Hofman","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105549_bib31","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3390\/cancers13092049","article-title":"Next-Generation sequencing with liquid biopsies from treatment-na\u00efve non-small cell lung carcinoma patients","volume":"13","author":"Hofman","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105549_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2023.100004","article-title":"Implementation of the clinical practice of liquid biopsies for thoracic oncology the experience of the RespirERA university hospital institute (Nice, France)","volume":"1","author":"Hofman","year":"2023","journal-title":"J. Liq. Biopsy"},{"key":"10.1016\/j.critrevonc.2026.105549_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101735","article-title":"Matched tissue and liquid biopsies for advanced non-small cell lung cancer patients A potentially indispensable complementary approach","volume":"35","author":"Hofman","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00428-023-03651-1","article-title":"Current challenges and practical aspects of molecular pathology for non-small cell lung cancers","volume":"484","author":"Hofman","year":"2024","journal-title":"Virchows Arch."},{"key":"10.1016\/j.critrevonc.2026.105549_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101628","article-title":"Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe","volume":"8","author":"Hofman","year":"2023","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105549_bib36","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/annonc\/mdz196","article-title":"Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?","volume":"30","author":"Hofman","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/cncy.22318","article-title":"Predictive molecular pathology in non-small cell lung cancer in France: the past, the present and the perspectives","volume":"128","author":"Hofman","year":"2020","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib38","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3390\/healthcare10091714","article-title":"Accelerating the development and validation of liquid biopsy for early cancer screening and treatment tailoring","volume":"10","author":"Horgan","year":"2022","journal-title":"Healthcare"},{"key":"10.1016\/j.critrevonc.2026.105549_bib39","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3390\/healthcare10091714","article-title":"Accelerating the development and validation of liquid biopsy for early cancer screening and treatment tailoring","volume":"10","author":"Horgan","year":"2022","journal-title":"Healthcare"},{"key":"10.1016\/j.critrevonc.2026.105549_bib40","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/jpm12010072","article-title":"Identifying the steps required to effectively implement Next-Generation sequencing in oncology at a national level in Europe","volume":"12","author":"Horgan","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.critrevonc.2026.105549_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104433","article-title":"From theory to practice: implementing next-generation sequencing and public health genomics in healthcare systems","volume":"201","author":"Horgan","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib42","article-title":"Precision oncology: a global perspective on implementation and policy development","volume":"11","author":"Horgan","year":"2025","journal-title":"J. C. O. Glob. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib43","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00428-024-03933-2","article-title":"Standardization through education of molecular pathology: a spotlight on the European Masters in Molecular Pathology","volume":"485","author":"Ili\u00e9","year":"2024","journal-title":"Virchows Arch."},{"key":"10.1016\/j.critrevonc.2026.105549_bib44","article-title":"Perspectives in educating molecular pathologists on liquid biopsy: toward integrative, equitable, and decentralized precision oncology","author":"Ili\u00e9","year":"2025","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib45","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3390\/curroncol30010053","article-title":"Impact of COVID-19 on cancer-related care in the United States: an overview","volume":"30","author":"Jabbal","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib46","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00428-025-04391-0","article-title":"Genetic variant interpretation in tumours in the French national ring trials Gen&Tiss - main criteria of improvement","volume":"488","author":"Kalimulaeva","year":"2026","journal-title":"Virchows Arch."},{"key":"10.1016\/j.critrevonc.2026.105549_bib47","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.3390\/cancers14143337","article-title":"Resistance to TKIs in EGFR-mutated non-small cell lung cancer: from mechanisms to new therapeutic strategies","volume":"14","author":"Koulouris","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105549_bib48","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s10555-024-10187-6","article-title":"Healthcare disparities, screening, and molecular testing in the changing landscape of non-small cell lung cancer in the United States: a review","volume":"43","author":"Kurzrock","year":"2024","journal-title":"Cancer Metastas-.-. Rev."},{"key":"10.1016\/j.critrevonc.2026.105549_bib49","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1038\/s41379-021-00880-0","article-title":"Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas","volume":"34","author":"Lin","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib50","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105549_bib51","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/1078-0432.CCR-24-3335","article-title":"Characterization of plasma cell-free DNA variants as of tumor or clonal hematopoiesis origin in 16,812 advanced cancer patients","volume":"31","author":"Magee","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105549_bib52","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1002\/cncr.32875","article-title":"Molecular testing for lung adenocarcinoma: is it time to adopt a \"plasma-first\" approach?","volume":"126","author":"Makarem","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105549_bib53","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer current: status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105549_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/2056-4538.70018","article-title":"Costs of biomarker testing in advanced non-small cell lung cancer: a global study comparing next-generation sequencing and single-gene testing","volume":"11","author":"Malapelle","year":"2025","journal-title":"J. Pathol. Clin. Res."},{"key":"10.1016\/j.critrevonc.2026.105549_bib55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2022.08.004","article-title":"The evolving role of liquid biopsy in lung cancer","volume":"172","author":"Malapelle","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105549_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinbiochem.2025.111072","article-title":"Laboratory medicine and sustainability: towards a green lab","volume":"142","author":"Mattman","year":"2026","journal-title":"J. Clin. Biochem."},{"key":"10.1016\/j.critrevonc.2026.105549_bib57","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1158\/2159-8290.CD-24-0519","article-title":"Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection","volume":"14","author":"Mazzone","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105549_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103891","article-title":"Clinical and technical insights of tumour mutational burden in non-small cell lung cancer","volume":"182","author":"Meri-Abad","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib59","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1016\/j.cllc.2020.02.021","volume":"21","author":"Minari","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105549_bib60","doi-asserted-by":"crossref","first-page":"12","DOI":"10.21873\/cdp.10502","article-title":"The NGS and PCR-based detection of EGFR mutations in liquid biopsy: a systematic review and meta-analysis compared with tissue biopsy in treatment-naive patients with non-small cell lung cancer","volume":"6","author":"Molina","year":"2026","journal-title":"Cancer Diagn. Progn."},{"key":"10.1016\/j.critrevonc.2026.105549_bib61","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib62","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/10408363.2023.2230290","article-title":"Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis","volume":"60","author":"Ntzifa","year":"2023","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.critrevonc.2026.105549_bib63","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13046-025-03398-4","article-title":"Fostering the implementation of liquid biopsy in clinical practice: meeting report 2024 of the European Liquid Biopsy Society (ELBS)","volume":"44","author":"Pantel","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105549_bib64","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib65","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/17410541.2025.2494982","article-title":"Genomics and the early diagnosis of lung cancer","volume":"22","author":"Pepe","year":"2025","journal-title":"Per. Med."},{"key":"10.1016\/j.critrevonc.2026.105549_bib66","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cllc.2022.11.007","article-title":"Liquid biopsy versus tissue biopsy to determine front line therapy in metastatic non-small cell lung cancer (NSCLC)","volume":"24","author":"Raez","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105549_bib67","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1089\/gte.2006.10.147","article-title":"Monitoring standards for molecular genetic testing in the United Kingdom, the Netherlands, and Ireland","volume":"10","author":"Ramsden","year":"2006","journal-title":"Genet. Test."},{"key":"10.1016\/j.critrevonc.2026.105549_bib68","doi-asserted-by":"crossref","first-page":"354","DOI":"10.6004\/jnccn.2025.0043","article-title":"NCCN guidelines insights: non-small cell lung cancer, Version 7.2025","volume":"23","author":"Riely","year":"2025","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.critrevonc.2026.105549_bib69","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib70","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-23-3321","article-title":"Measurement of ctDNA tumor fraction identifies informative negative liquid biopsy results and informs value of tissue confirmation","volume":"30","author":"Rolfo","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"S2","key":"10.1016\/j.critrevonc.2026.105549_bib71","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.annonc.2024.08.1237","article-title":"FRESH: the Gustave Roussy program to facilitate access to liquid biopsy for precision oncology in France","volume":"33","author":"Rouleau","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104605","article-title":"The next frontier of early lung cancer and minimal residual disease detection: is multiomics the solution?","volume":"92","author":"Rolfo","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105549_bib73","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.lungcan.2022.04.006","article-title":"Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications","volume":"168","author":"Scheffler","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105549_bib74","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3343\/alm.2017.37.5.365","article-title":"International Organization for Standardization (ISO) 15189","volume":"37","author":"Schneider","year":"2017","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.critrevonc.2026.105549_bib75","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1515\/cclm-2022-1152","article-title":"Embedding education into clinical laboratory professional training to foster sustainable development and greener practice","volume":"61","author":"Scott","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.critrevonc.2026.105549_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105771","article-title":"Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations","volume":"10","author":"Segu\u00ed","year":"2025","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105549_bib77","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jmoldx.2020.05.008","article-title":"Molecular Pathology Economics 101: an overview of molecular diagnostics coding, coverage, and reimbursement: a report of the association for molecular pathology","volume":"22","author":"Sireci","year":"2020","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.critrevonc.2026.105549_bib78","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-22-1749","article-title":"A Large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-Liquid)","volume":"29","author":"Sugimoto","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105549_bib79","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70463","article-title":"Lexicon for Clonal Hematopoiesis in Liquid Biopsy","volume":"19","author":"Tell","year":"2026","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.critrevonc.2026.105549_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107255","article-title":"Genomic characteristics and prognosis of lung cancer patients with MSI-H: a cohort study","volume":"181","author":"Tian","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105549_bib81","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/s41591-025-03613-x","article-title":"Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial","volume":"31","author":"Tr\u00e9dan","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105549_bib82","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.annonc.2024.06.018","article-title":"ESMO Recommendations on clinical reporting of genomic test results for solid cancers","volume":"35","author":"van de Haar","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib83","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.2928","article-title":"Biomarker-driven developments in the context of the new regulatory framework for companion diagnostics in the European Union","author":"Verbaanderd","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105549_bib84","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/jcp-2024-209514","article-title":"Implementation of an ISO 15189 accredited next generation sequencing service for cell-free total nucleic acid (cfTNA) analysis to facilitate driver mutation reporting in blood: the experience of a clinical diagnostic laboratory","volume":"78","author":"Werner","year":"2025","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105549_bib85","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41571-025-01085-z","article-title":"Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches","volume":"23","author":"Zhao","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:48:25Z","timestamp":1793087305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":85,"alternative-id":["S1040842826004361"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105549","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The de-centralization perspective for liquid biopsy use in thoracic pathology the way to go","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105549","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105549"}}